|  | MIMIC (N=23619) | eICU (N=35369) | Overall (N=58988) |
| --- | --- | --- | --- |
| **In-hospital Mortality** |  |  |  |
| Died | 4,650 (19.7%) | 4,870 (13.8%) | 9,520 (16.1%) |
| Survived | 18,969 (80.3%) | 30,499 (86.2%) | 49,468 (83.9%) |
| **Length of stay if died (days)** |  |  |  |
| Mean (SD) | 6.96 (7.27) | 8.71 (15.4) | 7.86 (12.1) |
| Median (Q1, Q3) | 4.54 (2.38, 8.96) | 5.38 (2.63, 10.8) | 4.96 (2.50, 9.84) |
| **Length of stay if survived (days)** |  |  |  |
| Mean (SD) | 5.07 (6.06) | 9.64 (10.9) | 7.89 (9.64) |
| Median (Q1, Q3) | 2.96 (1.75, 5.79) | 6.91 (4.27, 11.7) | 5.33 (2.85, 9.75) |
| **Mechanic Ventilation** |  |  |  |
| Received | 11,133 (47.1%) | 16,793 (47.5%) | 27,926 (47.3%) |
| Not received | 12,486 (52.9%) | 18,576 (52.5%) | 31,062 (52.7%) |
| **Renal Replacement Therapy** |  |  |  |
| Received | 1,762 (7.5%) | 2,683 (7.6%) | 4,445 (7.5%) |
| Did not receive | 21,857 (92.5%) | 32,686 (92.4%) | 54,543 (92.5%) |
| **Vasopressor(s)** |  |  |  |
| Received | 10,718 (45.4%) | 14,403 (40.7%) | 25,121 (42.6%) |
| Not received | 12,901 (54.6%) | 20,966 (59.3%) | 33,867 (57.4%) |
| **Cancer Present** |  |  |  |
| Cancer | 3,875 (16.4%) | 2,270 (6.4%) | 6,145 (10.4%) |
| Non-Cancer | 19,744 (83.6%) | 33,099 (93.6%) | 52,843 (89.6%) |
| **Age by group (years)** |  |  |  |
| 18 - 44 | 2,600 (11.0%) | 4,019 (11.4%) | 6,619 (11.2%) |
| 45 - 64 | 8,067 (34.2%) | 11,651 (32.9%) | 19,718 (33.4%) |
| 65 - 74 | 5,597 (23.7%) | 8,250 (23.3%) | 13,847 (23.5%) |
| 75 - 84 | 4,834 (20.5%) | 7,208 (20.4%) | 12,042 (20.4%) |
| 85 and higher | 2,521 (10.7%) | 4,241 (12.0%) | 6,762 (11.5%) |
| **Age overall (years)** |  |  |  |
| Mean (SD) | 65.0 (16.1) | 65.3 (16.5) | 65.2 (16.3) |
| Median (Q1, Q3) | 67.0 (55.0, 77.0) | 67.0 (55.0, 78.0) | 67.0 (55.0, 78.0) |
| **Sex** |  |  |  |
| Female | 9,924 (42.0%) | 16,982 (48.0%) | 26,906 (45.6%) |
| Male | 13,695 (58.0%) | 18,387 (52.0%) | 32,082 (54.4%) |
| **Race** |  |  |  |
| Asian | 664 (2.8%) | 476 (1.3%) | 1,140 (1.9%) |
| Black | 2,045 (8.7%) | 3,891 (11.0%) | 5,936 (10.1%) |
| Hispanic | 816 (3.5%) | 1,656 (4.7%) | 2,472 (4.2%) |
| Other | 4,039 (17.1%) | 1,964 (5.6%) | 6,003 (10.2%) |
| White | 16,055 (68.0%) | 27,382 (77.4%) | 43,437 (73.6%) |
| **SOFA continuous** |  |  |  |
| Mean (SD) | 5.93 (3.44) | 4.64 (3.08) | 5.16 (3.29) |
| Median (Q1, Q3) | 5.00 (3.00, 8.00) | 4.00 (2.00, 6.00) | 5.00 (3.00, 7.00) |
| **Charlson Comorbidity Index** |  |  |  |
| Mean (SD) | 5.89 (2.97) | 4.41 (2.91) | 5.00 (3.03) |
| Median (Q1, Q3) | 6.00 (4.00, 8.00) | 4.00 (2.00, 6.00) | 5.00 (3.00, 7.00) |
| **Full Code upon Admission** |  |  |  |
| Not Full Code | 1,330 (5.6%) | 3,227 (9.1%) | 4,557 (7.7%) |
| Full Code | 22,289 (94.4%) | 32,142 (90.9%) | 54,431 (92.3%) |
| **Full Code upon Discharge** |  |  |  |
| Not Full Code | 1,986 (8.4%) | 8,639 (24.4%) | 10,625 (18.0%) |
| Full Code | 21,633 (91.6%) | 26,730 (75.6%) | 48,363 (82.0%) |
| **Hypertension** |  |  |  |
| Hypertension absent | 8,131 (34.4%) | 15,191 (43.0%) | 23,322 (39.5%) |
| Hypertension present | 15,488 (65.6%) | 20,178 (57.1%) | 35,666 (60.5%) |
| **Heart Failure** |  |  |  |
| CHF absent | 15,698 (66.5%) | 26,742 (75.6%) | 42,440 (71.9%) |
| CHF present | 7,921 (33.5%) | 8,627 (24.4%) | 16,548 (28.1%) |
| **Asthma** |  |  |  |
| Asthma absent | 23,317 (98.7%) | 32,307 (91.3%) | 55,624 (94.3%) |
| Asthma present | 302 (1.3%) | 3,062 (8.7%) | 3,364 (5.7%) |
| **COPD** |  |  |  |
| COPD absent | 18,056 (76.4%) | 26,543 (75.0%) | 44,599 (75.6%) |
| COPD present | 5,563 (23.6%) | 8,826 (25.0%) | 14,389 (24.4%) |
| **CKD** |  |  |  |
| CKD Absent | 20,893 (88.5%) | 31,232 (88.3%) | 52,125 (88.4%) |
| CKD Present | 2,726 (11.5%) | 4,137 (11.7%) | 6,863 (11.6%) |
| **Solid Cancer** |  |  |  |
| Not Present | 22,189 (93.9%) | 34,001 (96.1%) | 56,190 (95.3%) |
| Present | 1,430 (6.1%) | 1,368 (3.9%) | 2,798 (4.7%) |
| **Hematological Cancer** |  |  |  |
| Not Present | 22,709 (96.1%) | 34,852 (98.5%) | 57,561 (97.6%) |
| Present | 910 (3.9%) | 517 (1.5%) | 1,427 (2.4%) |
| **Metastasized Cancer** |  |  |  |
| Not Present | 22,084 (93.5%) | 34,984 (98.9%) | 57,068 (96.7%) |
| Present | 1,535 (6.5%) | 385 (1.1%) | 1,920 (3.3%) |
| **Colon and Rectal (combined)** |  |  |  |
| Not Present | 23,417 (99.1%) | 35,141 (99.4%) | 58,558 (99.3%) |
| Present | 202 (0.9%) | 228 (0.6%) | 430 (0.7%) |
| **Liver and intrahepatic BD** |  |  |  |
| Not Present | 23,293 (98.6%) | 35,333 (99.9%) | 58,626 (99.4%) |
| Present | 326 (1.4%) | 36 (0.1%) | 362 (0.6%) |
| **Pancreatic** |  |  |  |
| Not Present | 23,382 (99.0%) | 35,303 (99.8%) | 58,685 (99.5%) |
| Present | 237 (1.0%) | 66 (0.2%) | 303 (0.5%) |
| **Other Digestive** |  |  |  |
| Not Present | 23,393 (99.0%) | 35,230 (99.6%) | 58,623 (99.4%) |
| Present | 226 (1.0%) | 139 (0.4%) | 365 (0.6%) |
| **Lung (including bronchus)** |  |  |  |
| Not Present | 23,013 (97.4%) | 34,836 (98.5%) | 57,849 (98.1%) |
| Present | 606 (2.6%) | 533 (1.5%) | 1,139 (1.9%) |
| **Other Respiratory** |  |  |  |
| Not Present | 23,580 (99.8%) | 35,341 (99.9%) | 58,921 (99.9%) |
| Present | 39 (0.2%) | 28 (0.1%) | 67 (0.1%) |
| **Other Mesothelial** |  |  |  |
| Not Present | 23,567 (99.8%) | 35,330 (99.9%) | 58,897 (99.8%) |
| Present | 52 (0.2%) | 39 (0.1%) | 91 (0.2%) |
| **Melanoma** |  |  |  |
| Not Present | 23,589 (99.9%) | 35,344 (99.9%) | 58,933 (99.9%) |
| Present | 30 (0.1%) | 25 (0.1%) | 55 (0.1%) |
| **Breast** |  |  |  |
| Not Present | 23,541 (99.7%) | 35,272 (99.7%) | 58,813 (99.7%) |
| Present | 78 (0.3%) | 97 (0.3%) | 175 (0.3%) |
| **Female Genital** |  |  |  |
| Not Present | 23,517 (99.6%) | 35,270 (99.7%) | 58,787 (99.7%) |
| Present | 102 (0.4%) | 99 (0.3%) | 201 (0.3%) |
| **Male Genital** |  |  |  |
| Not Present | 23,419 (99.2%) | 35,228 (99.6%) | 58,647 (99.4%) |
| Present | 200 (0.8%) | 141 (0.4%) | 341 (0.6%) |
| **Renal and Urinary** |  |  |  |
| Not Present | 23,405 (99.1%) | 35,244 (99.6%) | 58,649 (99.4%) |
| Present | 214 (0.9%) | 125 (0.4%) | 339 (0.6%) |
| **Central Nervous System** |  |  |  |
| Not Present | 23,494 (99.5%) | 35,190 (99.5%) | 58,684 (99.5%) |
| Present | 125 (0.5%) | 179 (0.5%) | 304 (0.5%) |
| **Endocrine** |  |  |  |
| Not Present | 23,575 (99.8%) | 35,360 (100.0%) | 58,935 (99.9%) |
| Present | 44 (0.2%) | 9 (0.0%) | 53 (0.1%) |
| **Lymphomas** |  |  |  |
| Not Present | 23,222 (98.3%) | 35,191 (99.5%) | 58,413 (99.0%) |
| Present | 397 (1.7%) | 178 (0.5%) | 575 (1.0%) |
| **Leukemia** |  |  |  |
| Not Present | 23,095 (97.8%) | 35,033 (99.1%) | 58,128 (98.5%) |
| Present | 524 (2.2%) | 336 (1.0%) | 860 (1.5%) |
| **Others** |  |  |  |
| Not Present | 22,061 (93.4%) | 34,969 (98.9%) | 57,030 (96.7%) |
| Present | 1,558 (6.6%) | 400 (1.1%) | 1,958 (3.3%) |